AstraZeneca sweeps out a PhIII asthma flop, a PD-1 drug and some other rejects as Q4 tally disappoints
AstraZeneca disposed a late-stage asthma flop and a few other early-stage assets this morning as it faced a growing chorus of criticism over its persistently weak revenue figures.
Researchers hit the eject button on tralokinumab in Q4, which went 0-for-3 in Phase III for uncontrolled asthma.
The failure here highlights a common problem with late-stage programs. The drug failed a Phase IIb study, but investigators wanted go after a niche after highlighting evidence of success in the subgroup analysis. That led them right into a blind alley. The IL-13 group also includes lebrikizumab, which came up with mixed data for Roche before the pharma giant sold it off.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.